

27 March 2018

ASX Announcement

Pentrox approved in Sweden, Norway, Poland and Croatia

Medical Developments International Limited (ASX: MVP) is delighted to announce that Pentrox has been approved for sale in Sweden, Norway, Croatia and Poland.

MVP CEO, Mr. John Sharman said, "These Marketing Authorisations brings the total approvals in Europe to 15 with a number of key countries, e.g. Germany and Finland expected soon."

European approval progress

- Approved
- DCP Approved (In National Phase)
- Future Approvals



Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888



About Pentrox

Pentrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Pentrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Pentrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About the Mundipharma network

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. For more information please visit: www.mundipharma.com.